Pharmaceutical & Life Sciences Manufacturing: Solar Panels for Manufacturing

Pharmaceutical and life sciences manufacturing runs one of the most solar-friendly load profiles in UK industry. Cleanroom HVAC, chilled water and compressed air run around the clock to hold validated temperature, humidity and pressure regimes, which gives the site a very high and remarkably flat electrical baseload. That baseload does not switch off at the weekend or overnight, and a large share of it falls squarely inside daylight hours, so on-site solar PV is consumed the moment it is generated rather than exported cheaply. For a sector where electricity is now the second or third largest controllable cost, and where customer and investor ESG scrutiny through SBTi and CDP is intense, a correctly sized rooftop array cuts unit cost and produces the verifiable Scope 2 reduction that supply-chain audits increasingly demand. The engineering challenge is not whether solar fits the load. It is planning the work around validated systems, dense rooftop plant and GMP change control, and that is exactly where sector-specific design earns its place.

Sizing solar for pharmaceutical and life sciences manufacturing

We size the array to your daytime baseload, not to the area of your roof. For a UK pharmaceutical or life sciences site, a typical system lands between 300 kW and 1,000 kW, using roughly 550 to 1,850 panels across 1,800 to 6,000 square metres of usable roof. A system in that range generates around 275,000 to 920,000 kWh a year in UK conditions, which for a plant with a flat 24/7 baseload is very largely self-consumed rather than spilled to export.

Rooftop plant density is high on pharma buildings, with air-handling units, chillers, ductwork and intakes competing for the same roof, so the usable area is often well below the gross roof footprint. We run a 3D shading study and coordinate the panel layout with existing plant and with HEPA intake positions before any figure is fixed. Every design starts from 12 months of half-hourly meter data, modelled shift by shift rather than as an annual average, so the specified size reflects how the plant actually draws power across a working week.

Costs and payback

A pharmaceutical and life sciences solar installation typically carries a project value of £240,000 to £850,000 fully installed, depending on system size, roof type and the amount of structural and electrical coordination required. On the strong, flat baseload this sector runs, that capital generally reaches simple payback in around 6 years, after which the system continues to generate for the remainder of a 25-year-plus panel life. Because solar PV qualifies as plant and machinery, most installs are fully expensed in year one under the Annual Investment Allowance, which improves the effective payback further for a corporation-tax payer.

Figure	Typical range
System size	300 kW to 1,000 kW
Panels	550 to 1,850
Roof area required	1,800 to 6,000 square metres
Project value (installed)	£240,000 to £850,000
Annual generation	275,000 to 920,000 kWh
Simple payback	Around 6 years

These are dossier-grounded ranges for planning purposes. The number that matters is the one we model from your own half-hourly data, and we share the full model so your finance team can stress-test it or feed it straight into your capital-appraisal process.

Compliance and regulation

Pharmaceutical and life sciences work sits under MHRA GMP, and that shapes how a solar install is planned rather than whether it can proceed. GMP change control applies to any work that touches a validated utility, so cleanroom HVAC, chilled water and compressed-air systems are treated as controlled from the outset. We plan the installation and the grid connection around your change-control procedures, and we produce the documentation your quality team needs to log the work.

• Cleanroom integrity: pressure regimes and HEPA filter integrity must be preserved throughout. Roof penetrations near intakes are designed carefully, and ballasted systems that need no penetration are preferred wherever the roof and structure allow.
• Business continuity: the only mandatory outage is the final grid connection, typically 4 to 8 hours. On validated production lines we plan that connection inside a scheduled shutdown or maintenance window, coordinated with your business-continuity requirements so there is no impact on validated production.
• Grid connection: a G99 application is required for connections above 17 kW per phase. DNO study responses commonly run to around 65 working days, with actual connection dates of 6 to 18 months on constrained networks, so we submit the application alongside the structural survey to start the clock early.
• Structure and fire safety: a roof structural survey is mandatory before any rail or ballast loading, and SPF1981 v3 fire-safety design is applied as standard, which insurers increasingly require for rooftop PV.
• Certification: MCS commercial certification underpins SEG eligibility, backed by NICEIC electrical registration and ISO 9001, 14001 and 45001, all of which enterprise procurement teams routinely check.

A representative project

The following scenario is representative and uses figures consistent with the dossier ranges above. A life sciences manufacturer runs cleanroom HVAC, chilled water and compressed air around the clock on a single site, with a very high and flat baseload and investor pressure to evidence an SBTi-aligned Scope 2 reduction. The building offers around 5,200 square metres of membrane roof once rooftop plant and intake clearances are accounted for.

A roof-mounted array of roughly 620 kW, using about 1,140 panels, generates in the region of 560,000 kWh a year. Because the baseload is flat and daytime-weighted, self-consumption sits high, so almost all of that generation displaces grid import at the full industrial rate rather than earning the lower export tariff. The grid connection is planned inside a validated shutdown under GMP change control, so there is no impact on validated production, and the generation data feeds directly into the group's CDP and SBTi submissions. On a project value inside the £240,000 to £850,000 band, that profile delivers simple payback in around 6 years. Every element of a real proposal would be confirmed against your own meter data and roof survey.

Funding the project

Most pharmaceutical installs are funded through a power purchase agreement or asset finance rather than capital, so solar need not compete with production-line investment. A PPA delivers day-one savings against your current grid tariff with zero capex, while asset finance keeps the asset on balance sheet and spreads the cost over 7 to 15 years, typically EBITDA-positive from year one. On top of the finance route, the Annual Investment Allowance, the Industrial Energy Transformation Fund for eligible sites, and Climate Change Agreements for energy-intensive sectors can all improve the numbers. We set out the full picture on our grants and funding page and break down the capital and per-kW figures on our cost page.

To see what a system would cost and return on your own site, request a fixed-price quote or run the numbers first with our savings calculator. If your operation spans more than one sub-sector, our pages on solar for food and beverage manufacturing and chemical and process manufacturing cover the load profiles and compliance regimes specific to each.